FEATURED COMPANIES
- 3M Company
- Allergan plc( Tobira)
- Astra Zeneca
- Genfit SA
- Gilead Sciences.
- Horizon Therapeutics
The Global NASH market valued at USD 3369.12 Million in the year 2020 is projected to grow due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. The market is expected to be driven by rise in advanced technology such as advanced clinical trials, special MRI technology, called MR-EFF (elastography fat fraction) to determine the percentage of fat and scarring present. This non-invasive diagnostic tool may eliminate the need for a liver biopsy.
Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.
North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.
On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.
Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.
Scope of the Report
Key Target Audience
Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.
North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.
On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.
Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.
Scope of the Report
- The report analyses the NASH Market by value (USD Million).
- The report analyses the NASH Market by Sales Channel - Hospital Pharmacy, Online Provider, Retail Pharmacy.
- The report analyses the NASH Market by By Drug Type - Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Others.
- The Global NASH Market has been analysed By Country - United States, Canada, Germany, France, United Kingdom, Italy, Japan, China, India, Mexico, Brazil
- The key insights of the report have been presented through the frameworks of SWOT analysis. Also, the attractiveness of the market has been presented by region, by Sales Channel, by Drug Type. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis AG, 3M Company, Zydus Cadila, Intercept Pharmaceuticals, SHIRE PLC , Allergan plc( Tobira), Genfit SA, Astra Zeneca, Horizon Therapeutics, Gilead Sciences.
- The report presents the analysis of NASH market for the historical period of 2016-2020 and the forecast period of 2021-2026.
Key Target Audience
- Healthcare an Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Frequently Asked Questions about the Global NASH Market
What is the estimated value of the Global NASH Market?
What is the growth rate of the Global NASH Market?
What is the forecasted size of the Global NASH Market?
Who are the key companies in the Global NASH Market?
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- 3M Company
- Allergan plc( Tobira)
- Astra Zeneca
- Genfit SA
- Gilead Sciences.
- Horizon Therapeutics
1. Report Scope and Methodology
4. Global NASH Market: An Analysis
5. Global NASH Market Segmentation, By Sales Channel (Value)
6. Global NASH Market Segmentation, By Drug Type (Value)
7. Global NASH Market: Regional Analysis
8. North America NASH Market: An Analysis
9. Europe NASH Market: An Analysis
10. Asia Pacific NASH Market: An Analysis
11. Latin America & Middle East Africa NASH Market: An Analysis
12. Global NASH Market Dynamics
13. Market Attractiveness and Strategic Analysis
14. Competitive Landscape
List of Figures
Note: Product cover images may vary from those shown
- Novartis AG
- 3M Company
- Zydus Cadila
- Intercept Pharmaceuticals
- SHIRE PLC
- Allergan plc( Tobira)
- Genfit SA
- Astra Zeneca
- Horizon Therapeutics
- Gilead Sciences.
Note: Product cover images may vary from those shown
LOADING...
